T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment

NCT02644889 ·Status: UNKNOWN

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

NCT02575560 ·Status: COMPLETED

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

NCT02959749 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

T790M Plasma Testing Methodology Comparison and Clinical Validation

NCT02997501 ·Status: COMPLETED ·Phase: PHASE3

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

NCT03544814 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

NCT02914990 ·Status: COMPLETED ·Phase: PHASE1

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

NCT03758677 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

NCT02788058 ·Status: UNKNOWN ·Phase: PHASE2

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

NCT07298148 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)

NCT02043002 ·Status: COMPLETED ·Phase: NA

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT04324164 ·Status: RECRUITING

A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

NCT02738684 ·Status: UNKNOWN

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

NCT04811001 ·Status: UNKNOWN ·Phase: PHASE2

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

NCT01106781 ·Status: COMPLETED

Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

NCT02381808 ·Status: UNKNOWN

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

NCT02886195 ·Status: UNKNOWN ·Phase: PHASE3

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

NCT02988141 ·Status: UNKNOWN

Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

NCT04122833 ·Status: UNKNOWN

Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer

NCT02169349 ·Status: COMPLETED

Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing

NCT03609918 ·Status: COMPLETED

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC

NCT06422546 ·Status: RECRUITING

A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples

NCT01382992 ·Status: UNKNOWN

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

NCT04322890 ·Status: RECRUITING ·Phase: PHASE2

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

NCT04768491 ·Status: UNKNOWN

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

NCT03137264 ·Status: COMPLETED